Reglan and Tardive Dyskinesia: What Arizona Patients Should Know

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Legal Concerns

If you or a loved one has taken Reglan and noticed uncontrollable muscle movements, you may be experiencing tardive dyskinesia. This condition is a known side effect of long-term metoclopramide use. Drawing from decades of medical research and patient safety data, this page answers common questions about Reglan-related tardive dyskinesia in Arizona.

Medical Evidence: Reglan and Tardive Dyskinesia Risk

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux disease (GERD) and diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved prescribing information for Reglan includes a boxed warning stating that metoclopramide can cause TD, and that the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning emphasizes that Reglan should be used for the shortest duration necessary and that treatment should be periodically reassessed. For patients with GERD, the maximum approved treatment duration is 12 weeks, and for diabetic gastroparesis, treatment beyond 12 weeks should be avoided unless longer use is unavoidable, in which case routine monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after the medication is discontinued. The prescribing information notes that metoclopramide can also suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic link between Reglan and TD involves the drug's dopamine receptor-blocking properties, which can lead to supersensitivity of dopamine receptors in the basal ganglia, a brain region involved in movement control. This pathway is well-documented in the medical literature and is consistent with the known adverse effects of other dopamine-blocking agents.

Legal Implications: Arizona Statute of Limitations for Reglan Claims

For patients in Arizona who have developed TD after taking Reglan, several legal and medical considerations arise. The statute of limitations for filing a personal injury lawsuit in Arizona is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because TD may not become apparent until months or years after Reglan use begins. The delay between exposure and documented harm can complicate the legal process, as patients must establish when they first noticed symptoms and when they connected those symptoms to Reglan. Medical records documenting the onset of TD and the duration of Reglan use are essential for building a case. Another key risk anchor is the adequacy of warnings provided to patients and healthcare providers. The FDA-approved labeling includes a boxed warning and specific precautions, but patients may not have been adequately informed about the risk of TD, especially if they used Reglan for longer than the recommended 12-week period. The prescribing information states that Reglan has not been shown to be safe or effective for GERD treatment beyond 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite this, some patients may have been prescribed Reglan for extended periods, increasing their risk. Additionally, the labeling notes that Reglan tablets are not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Off-label use or failure to monitor for TD could be relevant in legal claims.

Building a Case: Evidence and Expert Testimony

Attorney-related considerations for affected patients include the need to gather evidence of Reglan use, such as prescription records and pharmacy logs, as well as medical documentation of TD diagnosis. Expert testimony from neurologists or pharmacologists may be required to establish the causal link between Reglan and the patient's TD. The timeline between exposure and harm is particularly important in Arizona, where the statute of limitations may begin when the patient knew or should have known that Reglan caused their injury. Patients who developed TD years after stopping Reglan may face challenges in proving that the injury was discovered within the statutory period. In summary, Reglan use carries a well-documented risk of tardive dyskinesia, as highlighted in the FDA's boxed warning. Patients in Arizona who have developed TD after taking Reglan should be aware of the statute of limitations and the importance of timely legal action. The adequacy of warnings, duration of treatment, and timeline of symptom onset are critical factors in evaluating potential claims. Medical records and expert testimony are essential for establishing the link between Reglan and TD, and for navigating the legal process.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Arizona?

In Arizona, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or reasonably should have been discovered. This means that patients must file their lawsuit within two years of becoming aware of their TD and its link to Reglan. It is crucial to consult with an attorney promptly to ensure compliance with this deadline.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) can cause tardive dyskinesia through its dopamine receptor-blocking properties. This can lead to supersensitivity of dopamine receptors in the basal ganglia, a brain region involved in movement control. The risk increases with longer treatment duration and higher cumulative doses, as highlighted in the FDA's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What evidence is needed to file a Reglan TD claim in Arizona?

To file a claim, patients need evidence of Reglan use (prescription records, pharmacy logs), medical documentation of a tardive dyskinesia diagnosis, and records showing the timeline of symptoms. Expert testimony from neurologists or pharmacologists may be required to establish the causal link. It is also important to document when the injury was discovered to meet the statute of limitations.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Reglan Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.